Results 71 to 80 of about 2,071 (173)
MedComm, Volume 7, Issue 11, November 2026.Neurodegenerative diseases share convergent risk architectures and pathological mechanisms, yet diverge in selective vulnerability, clinical presentation, and therapeutic responsiveness. This review integrates cross‐disease epidemiology, pathophysiology, diagnosis, and treatment, highlighting the transition from symptomatic care toward biomarker‐guided
Zimeng He +4 more
wiley +1 more source
Physics and Imaging in Radiation Oncology, 2023 Background and purpose: Accurate dosimetry in Ultra-High Dose Rate (UHDR) beams is challenging because high levels of ion recombination occur within ionisation chambers used as reference dosimeters.
John Cotterill +7 more
doaj +1 more source
Movement Disorders, Volume 41, Issue 10, Page 2712-2722, October 2026.Abstract Background Although not confirmed, some studies have suggested that elevated homocysteine levels are common in patients with Huntington's disease (HD). Its clinical relevance remains unclear. Objectives We aimed to assess vitamin B and homocysteine levels in HD patients and explore the relationships among hyperhomocysteinemia, vitamin B ...
Salomé Puisieux +16 more
wiley +1 more source
Medical Physics, Volume 53, Issue 10, October 2026.Abstract Background Proton FLASH radiotherapy has demonstrated promising normal tissue sparing for similar tumor control at ultra‐high dose rates (> 40 Gy/s), but systematic investigation of dose‐rate‐dependent biological mechanisms is limited. Most existing proton platforms operate within a narrow dose‐rate range. Synchrotron‐based systems are further
Zongsheng Hu +4 more
wiley +1 more source
International Journal of Radiation Oncology, Biology, PhysicsPurpose Large, rapid extracellular oxygen transients (ΔpO2) have been measured in vivo during Ultra-High Dose Rate (UHDR) radiotherapy; however, it has been unclear if this matches intracellular oxygen levels.
A. Petusseau +4 more
semanticscholar +1 more source
Systematic Review of the Huntington's Disease Drug Development Pipeline, 2014 to 2025
Movement Disorders, Volume 41, Issue 9, Page 2267-2277, September 2026.Abstract Background In the past decade, significant advances have improved our understanding of the mechanisms underlying HD pathobiology leading to several putative therapeutic targets for HD. Objective The aim was to describe the Huntington's disease (HD) drug development clinical pipeline.
Pavlina Konstantinova +5 more
wiley +1 more source
Powering Neurology Drug Development Trials to Reduce False Negative Results
Clinical and Translational Science, Volume 19, Issue 9, September 2026.ABSTRACT Sensitive and reliable measurement of therapeutic outcomes in neurology drug trials remains challenging. Clinical rating scales and their total scores are often considered the gold standard and used as primary efficacy endpoints in studies because of their acceptance by the clinical community and regulators.
Hiromasa Mori +3 more
wiley +1 more source
Scientific ReportsA growing body of pre-clinical research has demonstrated the potential of ultra-high dose-rate (UHDR) radiotherapy to reduce normal tissue toxicity while maintaining tumor control.
Deae-eddine Krim +5 more
doaj +1 more source
Medical Physics (Lancaster)Recent studies suggest that radiotherapy at ultrahigh dose rates (>40 Gy/s, FLASH) offers normal tissue sparing effects while maintaining tumor control.
Ling-Shu Yin +6 more
semanticscholar +1 more source
Functional and Structural Evidence of Neurofluid Circuit Aberrations in Huntington Disease
Annals of Clinical and Translational Neurology, Volume 13, Issue 7, Page 1433-1442, July 2026.ABSTRACT Objective Disrupted neurofluid regulation may contribute to neurodegeneration in Huntington disease (HD). Because neurofluid pathways influence waste clearance, inflammation, and the distribution of central nervous system (CNS)–delivered therapeutics, understanding their dysfunction is increasingly important as targeted treatments emerge.
Kilian Hett +8 more
wiley +1 more source